Request Trial
new-frontier-old-west
4 November 2013Biotech

New frontiers: potential barriers to patenting induced totipotent stem cell technology

It has for some years been possible to create pluripotent stem cells (stem cells capable of differentiating into many, but not all, other cell types of the body) from fully differentiated adult cells (so called ‘induced pluripotent stem cells’ [iPS cells]).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight
21 September 2026   Judges agreed with the Oxford University spin-out that MGI Tech was likely to infringe Oxford’s patent, and banned sales of certain Cyclone devices to preserve the one-player-market status quo.
Biotech
Amgen hit with lawsuit over its proposed Opdivo biosimilar
16 September 2026   BMS is stepping up its defence of its blockbuster cancer drug Opdivo as Amgen moves closer to the biosimilar market.
Biotech
Australian biotech sues Grail over multi-cancer blood test
15 September 2026   Grail is facing a patent infringement lawsuit over its Galleri cancer detection test, as Clinical Genomics seeks to enforce its intellectual property while no longer being commercially operational.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

US firm hires litigation pro whose clients include Pfizer, Medtronic
Oxford Nanopore scores urgent injunction at UPC in DNA sequencing fight
Leading European patent litigator to join Carpmaels & Ransford
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Amgen hit with lawsuit over its proposed Opdivo biosimilar
Beyond the primary patent: How pharma can build competitive barriers
Australian biotech sues Grail over multi-cancer blood test
Patent lawyers and judges discuss lofty UPC issues in grand London venue